

Weight Reduction Programs in Obese Sleep Apnea Patients: The Role of the Mediterranean Diet

Christopher Papandreou*

Department of Social Medicine, Preventive Medicine and Nutrition Clinic, Medical School, University of Crete, Heraklion, Greece

Editorial

Obstructive Sleep Apnoea Syndrome (OSAS) is considered to be one of the most prevalent sleep-related breathing disorders, with an enormous effect on public health. Approximately 2-4% of the general adult population experiences some degree of this syndrome [1]. This percentage increases even more with obesity, up to 20-40%, especially in individuals with an excessive Body Mass Index (BMI) ≥ 30 kg/m² [2]. OSAS is associated with significant systemic consequences, including cardiovascular morbidity and mortality, and the risk increases with the severity of the syndrome [3]. The pathophysiology underlying the link between OSAS and the cardiovascular system is attributed largely to systemic inflammation and oxidative stress, which are both contributors to endothelial dysfunction [4]. The treatment modalities of OSAS include Continuous Positive Airway Pressure (CPAP), weight loss, upper airway surgery, and oral devices [5]. CPAP is the first line therapy, as a means of maintaining upper airway patency [6], and it is well known that this intervention reduces morbidity and mortality [7]. In severe cases of OSAS the weight loss strategy is essential and must accompany CPAP treatment [8]. A growing body of evidence in OSAS supports the beneficial role of weight reduction, induced by diet alone [9-12] or in combination with exercise [13], leading to a reduction in apnoeas and hypopnoeas. A recent study conducted at the University of Crete examined the effect of the Mediterranean diet (MD) compared with that of a prudent diet on obese adults with moderate-to-severe OSAS who were treated with CPAP while receiving counselling to increase their physical activity [14]. The results showed that people following the MD had a reduced number of disturbances, known as apnoeas, during the rapid eye movement (REM) stage of sleep, which usually accounts for approximately 25% of total sleep during the night. Recent reports have related an increase in disturbances during REM sleep with the risk of developing significant systemic consequences like diabetes type II. However, its clinical significance remains unclear.

The findings also revealed that people following the MD also showed a greater adherence to the calorie restricted diet, an increase in physical activity and a greater decrease in abdominal fat. The MD promotes satiation and encourages consumption of a variety of palatable foods, optimizing adherence to a caloric restricted diet [15]. It is also possible that the MD along with increased physical activity could promote changes of relevant anthropometric determinants such as waist size and finally better outcome. It has been suggested that abdominal fat is a risk factor for OSAS in obese patients [16]. It is related with a reduction in pharyngeal lumen size due to fatty tissue within the airway or in its lateral walls, and a decrease in upper airway muscle protective force due to fatty deposits in the muscle. It has also been reported that abdominal fat is associated with reduced upper airway size secondary to the mass effect of the large abdomen on the chest wall and tracheal traction [17]. Moreover, an association between increased Body Mass Index (BMI) and the development of hypoventilation is well recognized, as abdominal fat accumulation is known to impair diaphragmatic excursion and rib cage expansion [18]. Since, diaphragm consists the main inspiratory muscle during REM sleep [19], abdominal obesity may mechanically affect the expansion

of the diaphragm, probably by encroaching into the chest by the chest wall or diaphragm or by impeding the descent of the diaphragm during forced inspiration [20]. While obesity alone does not account for the development of hypoventilation, it would be possible that by decreasing abdominal fat, breathing would have improved during REM sleep. Therefore, it is likely that the patients in the MD group reduced AHI/REM more than those in the PD group because of the greater reduction in abdominal fat, via an improvement in the mechanical load associated with OSAS [21].

Another possible explanation for the AHI/REM improvement in the MD group compared to the PD group would be through inflammation, although not examined in the aforementioned study. It has been reported that inflammation is associated with a reduced muscle and diaphragm contractibility [22,23]. The inflammation of upper airway tissues is primarily related to abdominal fat [24]. Dietary components may also contribute to the inflammation seen in OSAS. On the other hand, the Mediterranean dietary pattern has shown anti-inflammatory effects due to its composition [25]. Finally, further studies in a larger sample are needed to clarify the role of the MD in the therapeutic plan of OSAS patients taking into account its anti-inflammatory properties.

References

1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, et al. (1993) The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med* 328: 1230-1235.
2. Kyzer S, Charuzi I (1998) Obstructive sleep apnea in the obese. *World J Surg* 22: 998-1001.
3. Marin JM, Carrizo SJ, Vicente E, Agusti AG (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet* 365: 1046-1053.
4. Yim-Yeh S, Rahangdale S, Nguyen AT, Stevenson KE, Novack V, et al. (2011) Vascular dysfunction in obstructive sleep apnea and type 2 diabetes mellitus. *Obesity (Silver Spring)* 19: 17-22.
5. Freedman N (2010) Treatment of obstructive sleep apnea syndrome. *Clin Chest Med* 31: 187-201.
6. Hirshkowitz M, Sharafkhaneh A (2005) Positive airway pressure therapy of OSA. *Semin Respir Crit Care Med* 26: 68-79.
7. Jenkinson C, Davies RJ, Mullins R, Stradling JR (1999) Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for

*Corresponding author: Christopher Papandreou, Department of Social Medicine, Preventive Medicine and Nutrition Clinic, Medical School, University of Crete, Heraklion, Greece, Tel: +30 6974303995; E-mail: papchris10@gmail.com

Received July 19, 2012; Accepted July 19, 2012; Published July 25, 2012

Citation: Papandreou C (2012) Weight Reduction Programs in Obese Sleep Apnea Patients: The Role of the Mediterranean Diet. *J Nutr Food Sci* 2:e112. doi:10.4172/2155-9600.1000e112

Copyright: © 2012 Papandreou C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

- obstructive sleep apnoea: a randomised prospective parallel trial. *Lancet* 353: 2100-2105.
8. Hertegonne K, Bauters F (2010) The value of auto-adjustable CPAP devices in pressure titration and treatment of patients with obstructive sleep apnea syndrome. *Sleep Med Rev* 14: 115-119.
 9. Kajaste S, Brander PE, Telakivi T, Partinen M, Mustajoki P (2004) A cognitive-behavioral weight reduction program in the treatment of obstructive sleep apnea syndrome with or without initial nasal CPAP: a randomized study. *Sleep Med* 5: 125-131.
 10. Kansanen M, Vanninen E, Tuunainen A, Pesonen P, Tuononen V, et al. (1998) The effect of a very low-calorie diet-induced weight loss on the severity of obstructive sleep apnoea and autonomic nervous function in obese patients with obstructive sleep apnoea syndrome. *Clin Physiol* 18: 377-385.
 11. Johansson K, Neovius M, Lagerros YT, Harlid R, Rössner S, et al. (2009) Effect of a very low energy diet on moderate and severe obstructive sleep apnoea in obese men: a randomised controlled trial. *BMJ* 339: b4609.
 12. Tuomilehto HP, Seppä JM, Partinen MM, Peltonen M, Gylling H, et al. (2009) Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. *Am J Respir Crit Care Med* 179: 320-327.
 13. Barnes M, Goldsworthy UR, Cary BA, Hill CJ (2009) A diet and exercise program to improve clinical outcomes in patients with obstructive sleep apnea—a feasibility study. *J Clin Sleep Med* 5: 409-415.
 14. Papandreou C, Schiza SE, Bouloukaki I, Hatzis CM, Kafatos AG, et al. (2012) Effect of Mediterranean diet versus prudent diet combined with physical activity on OSAS: a randomised trial. *Eur Respir J* 39: 1398-1404.
 15. Schröder H (2007) Protective mechanisms of the Mediterranean diet in obesity and type 2 diabetes. *J Nutr Biochem* 18: 149-160.
 16. Uçok K, Aycicek A, Sezer M, Genc A, Akkaya M, et al. (2009) Aerobic and anaerobic exercise capacities in obstructive sleep apnea and associations with subcutaneous fat distributions. *Lung* 187: 29-36.
 17. Seidell JC (2010) Waist circumference and waist/hip ratio in relation to all-cause mortality, cancer and sleep apnea. *Eur J Clin Nutr* 64: 35-41.
 18. Schäfer H, Pauleit D, Sudhop T, Gouni-Berthold I, Ewig S, et al. (2002) Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. *Chest* 122: 829-839.
 19. Bennett JR, Dunroy HM, Corfield DR, Hart N, Simonds AK, et al. (2004) Respiratory muscle activity during REM sleep in patients with diaphragm paralysis. *Neurology* 62: 134-137.
 20. Lazarus R, Gore CJ, Booth M, Owen N (1998) Effects of body composition and fat distribution on ventilatory function in adults. *Am J Clin Nutr* 68: 35-41.
 21. Patil SP, Schneider H, Marx JJ, Gladmon E, Schwartz AR, et al. (2007) Neuromechanical control of upper airway patency during sleep. *J Appl Physiol* 102: 547-556.
 22. Reid MB, Lännergren J, Westerblad H (2002) Respiratory and limb muscle weakness induced by tumor necrosis factor- α : involvement of muscle myofilaments. *Am J Respir Crit Care Med* 166: 479-484.
 23. Wilcox PG, Wakai Y, Walley KR, Cooper DJ, Road J (1994) Tumour necrosis factor α decreases in vivo diaphragm contractility in dogs. *Am J Respir Crit Care Med* 150: 1368-1373.
 24. Elks CM, Francis J (2010) Central adiposity, systemic inflammation, and the metabolic syndrome. *Curr Hypertens Rep* 12: 99-104.
 25. Galland L (2010) Diet and inflammation. *Nutr Clin Pract* 25: 634-640.